Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  KOREA EXCHANGE (KOSDAQ)  >  Celltrion, Inc.    068270   KR7068270008

CELLTRION, INC. (068270)
Mes dernières consult.
Most popular
Report
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( KRW)
Sales 2017 941 B
EBIT 2017 492 B
Net income 2017 381 B
Debt 2017 207 B
Yield 2017 -
Sales 2018 1 292 B
EBIT 2018 707 B
Net income 2018 552 B
Finance 2018 19,9 B
Yield 2018 -
P/E ratio 2017 95,36
P/E ratio 2018 67,53
EV / Sales2017 38,5x
EV / Sales2018 27,9x
Capitalization 36 006 B
More Financials
Company
Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals.It operates through the Biopharmaceuticals, Chemical Drugs and Others businesses.Its products include remsima and biosimilars.The company was founded on February 27, 1991 and is headquartered in Incheon,... 
More about the company
Surperformance© ratings of Celltrion, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on CELLTRION, INC.
01/09 Celltrion overtakes Hyundai Motor in market cap
2017 STAR STOCKS : Samsung Electronics, Celltrion
2017 HIKMA PHARMACEUTICALS : South Korea’s Celltrion ink MENA product launch de..
2017 CELLTRION : Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimil..
2017 PFIZER : `No plans to launch second approved Remicade biosimilar in US`
2017 CELLTRION : Short sellers target KOSDAQ`s two high flyers
2017 CELLTRION : Biopharma firms are all the rage on the Kosdaq
2017 CELLTRION : Healthcare presents positive results for Truxima
2017 CELLTRION : taps Oracle Health Sciences Safety Solutions to Help Bring Cost-Effe..
2017 CELLTRION : Taps Oracle Health Sciences Safety Solutions to Help Bring Cost-Effe..
More news
Sector news : Biotechnology & Medical Research - NEC
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Biotechnology & Medical Research - NEC
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 199 682  KRW
Spread / Average Target -31%
EPS Revisions
Managers
NameTitle
Wu-Sung Ki Co-Chief Executive Officer & Director
Hyung-Ki Kim Co-Chief Executive Officer & Director
Jung-Jin Seo Director
Dong-Il Kim Outside Director
Joseph Lee Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.33 774
IQVIA HOLDINGS INC2.37%20 782
LONZA GROUP0.76%20 640
INCYTE CORPORATION-4.65%19 399
ALNYLAM PHARMACEUTICALS, INC.-1.42%12 192
NEKTAR THERAPEUTICS16.21%11 048